Opexa Therapeutics (NASDAQ:OPXA) is a biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The company's leading product candidate has the potential to address the significant unmet medical needs of the large multiple sclerosis (MS) patient population.

Opexa's lead therapy, Tcelna® , a cellular immunotherapy has completed a Phase 2b clinical study for the treatment of MS that is specifically tailored to each patient's disease profile. Opexa believes the potential combination of efficacy, superior safety, improved tolerability and administration may position Tcelna as the MS treatment of choice as compared to existing therapeutics.

Management Team

Board of Directors

Board of Directors Committee Listing:

Audit Committee:*

Michael Richman - Chair
Timothy Barabe
Gail Maderis

Compensation Committee:

Tim Barabe - Chair
Gail Maderis
Michael Richman

Governance and Nominating Committee:

Gail Maderis - Chair
Tim Barabe
Michael Richman

Science Committee:

Hans-Peter Hartung - Chair
Michael Richman

*The Board has determined that Michael Richman, Timothy Barabe and Gail Maderis qualify as an "audit committee financial expert" as defined in SEC regulations and also possesses the financial sophistication and requisite experience as required under NASDAQ listing standards.